You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Combination of Tremelimumab and Durvalumab

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mesothelioma Trial in Durham, Houston (Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemo plus

Not yet recruiting
  • Mesothelioma
  • Durvalumab / tremelimumab
  • Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
  • Durham, North Carolina
  • +1 more
Jul 5, 2023

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Small Cell Lung Carcinoma Trial in Omaha (Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in

Terminated
  • Small Cell Lung Carcinoma
  • Durvalumab + Tremelimumab in combination with carboplatin and etoposide
  • Durvalumab in combination with carboplatin and etoposide
  • Omaha, Nebraska
    University of Nebraska Medical Center
Feb 24, 2022

Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies Trial in Worldwide (Durvalumab / Tremelimumab Combination

Active, not recruiting
  • Pediatric Cancer
  • +2 more
  • Durvalumab / Tremelimumab Combination Therapy
  • Baltimore, Maryland
  • +18 more
Nov 3, 2022

Hepatocellular Carcinoma Trial (Livmoniplimab, Budigalimab, Durvalumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 26, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)

Active, not recruiting
  • Biliary Tract Neoplasms
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 26, 2021

Malignant Glioma, Recurrent Glioblastoma Trial in Chicago (biological, other, procedure)

Completed
Has Results
  • Malignant Glioma
  • Recurrent Glioblastoma
  • Durvalumab
  • +3 more
  • Chicago, Illinois
    Northwestern University
Mar 17, 2022

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Infiltrating Bladder Urothelial Carcinoma Trial in France (Durvalumab, Tremelimumab, MVAC Protocol)

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma
  • Paris, Ile De France, France
  • +14 more
Apr 21, 2022

Hepatocellular Carcinoma Trial in Worldwide (Tremelimumab, Durvalumab, Bevacizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Tremelimumab
  • +2 more
  • Phoenix, Arizona
  • +43 more
Jun 22, 2022

Tumor, Solid Trial in Lexington (Durvalumab and Tremelimumab)

Recruiting
  • Tumor, Solid
  • Durvalumab and Tremelimumab
  • Lexington, Kentucky
    Markey Cancer Center
Aug 19, 2021

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,

Recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • Frankfurt am Main, Germany
    Krankenhaus Nordwest
Jun 23, 2022

Advanced Malignancy Trial in Changchun (durvalumab, tremelimumab + durvalumab)

Completed
  • Advanced Malignancy
  • Changchun, China
  • +1 more
Aug 12, 2021

Soft Tissue Sarcoma Trial in Tucson, Baltimore, Pittsburgh (Combination Radiation, Immunotherapy, Surgery)

Recruiting
  • Soft Tissue Sarcoma
  • Combination Radiation, Immunotherapy, Surgery
  • Tucson, Arizona
  • +2 more
Jan 30, 2022

Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Pexa-Vec)

Active, not recruiting
Has Results
  • Colorectal Cancer
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA Trial in Bobigny (Durvalumab/Tremelimumab in neoadjuvant

Not yet recruiting
  • BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
  • Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
  • Bobigny, France
    Hospitl Avicenne
Sep 13, 2023

Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer Trial in Villejuif (Durvalumab, Tremelimumab, SBRT)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Villejuif, Val De Marne, France
    Gustave Roussy
Jul 21, 2021

Advanced Solid Malignancies Trial in Worldwide (MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab)

Active, not recruiting
Has Results
  • Advanced Solid Malignancies
  • MEDI4736 (Durvalumab)
  • MEDI4736 (Durvalumab) + Tremelimumab
  • Santa Rosa, California
  • +78 more
Aug 18, 2022